Mark Lappe
Mark Lappe has made 2 open-market purchases worth $1.8M since Sep 28, 2026, in 1 company. The latest: $849k of INBX, filed Oct 14, 2026, scored 43 out of 100.
CEO, Inhibrx Biosciences, Inc.
Follow Mark Lappe, freeOpen the live feed
A free account gets an alert the minute a new buy or sale is filed.
Purchases
| Filed | Stock | Stake | Score | Bought | 1 week | 1 month |
|---|---|---|---|---|---|---|
| Oct 14 Form 4 (opens sec.gov) |
INBXInhibrx Biosciences, Inc. · CEOCEO | +1% stake | 43 | $849k 10,040 at $84.56 |
+7.3% | waiting |
| Sep 28 Form 4 (opens sec.gov) |
INBXInhibrx Biosciences, Inc. · CEOCEO · 2 insiders buying | +1% stake | 55 | $999k 10,000 at $99.88 |
−10.9% | −29.7% |
Track record (hypothetical): a week after the filing, these buys averaged −1.8% (50% up, 2 measured); a month after, −29.7% (0% up, 1 measured).
Questions
What stock has Mark Lappe bought?
INBX (Inhibrx Biosciences, Inc.), all on the open market and reported on SEC Form 4.
When did Mark Lappe last buy?
Oct 14, 2026: 10,040 shares of INBX at $84.56, $849k in all (Form 4 (opens sec.gov)).
Has Mark Lappe filed a notice of a planned sale?
Not in the filings on record. A Form 144 is the notice an insider must file before selling restricted or control shares, and it lands on EDGAR before the sale is reported.
Is Mark Lappe a routine or an opportunistic buyer?
There isn't enough history to say yet.
Data as of Oct 14, 2026, from SEC EDGAR Form 4 filings: open-market purchases (code P) of $25,000 or more, and open-market sales. Every row links to its filing. Scores summarise what a filing says (how the score works); outcomes are hypothetical, from the first close after the filing, and past results don't predict future ones. Disclaimer